A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections

Kohei Hara, Shigeru Kohno, Hironobu Koga, Akira Saito, Mitsuhide Ohmichi, Yohmei Hiraga, Kazuo Takebe, Tsukasa Yoshida, Toshiharu Ito, Akira Watanabe, Kazuo Sato, Kikuo Onuma, Masataka Katsu, Akira Ohishi, Junzaburo Kabe, Hitoshi Arioka, Noriko Nakajima, Atsuhito Yoshizawa, Koichiro Nakata, Yoshitaka NakamoriTatsuo Nakatani, Kohji Narui, Eiyasu Tsuboi, Kaoru Shimada, Hajime Goto, Takashi Inamatsu, Makoto Kodaira, Yoshishige Masuda, Yasuyuki Sano, Ken Koshino, Yasuo Arai, Jingoro Shimadaand, Masaki Yoshida, Hiroichi Tanimoto, Hiroyuki Kobayashi, Hisashi Inoue, Masaru Koyama, Shigeki Odagiri, Masanori Matsumura, Kaneo Suzuki, Yasuhiko Ashikari, Akira Shoji, Masaaki Arakawa, Kouichi Wada, Takashi Kawashima, Masanaga Takatoh, Shigeyuki Hoshino, Fumihide Iwata, Naoki Osaki, Yoshinori Shimazu, Osamu Sekine, Yasutoshi Suzuki, Nobuki Aoki, Saburo Izumi, Susumu Kishimoto, Tomiya Masuno, Seiji Hayashi, Eiro Tsubura, Masaru Nakagawa, Tsuyoshi Igarashi, Kiyoshi Komuta, Mitsunori Sakatani, Mitsumasa Ogawara, Norio Ochi, Norio Itakura, Masami Ito, Naoyoshi Kojiro, Toshiyuki Ikeda, Takahiko Yoshimoto, Hideki Hara, Toru Kumagai, Fumio Miki, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Masaru Sumi, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Michio Yamakido, Kenji Hasegawa, Kenichiro Sadamoto, Masao Kuwabara, Yukio Nishimoto, Jitsuo Yanagida, Masato Yukutake, Yukikazu Awaya, Osamu Kurimura, Hideo Sasaki, Akimasa Oune, Hisakazu Muranishi, Masayuki Miyazaki, Kotaro Oizumi, Yoichiro Ichikawa, Hisato Tokunaga, Masaru Nasu, Keizo Matsumoto, Atsushi Takahashi, Hirofumi Tanaka, Mikio Taguchi, Harumi Shishido, Hideaki Nagai, Koji Sato, Atsuyuki Kurashima, Kiyoshi Shima, Shinobu Takenaka, Atsushi Saito, Yuei Irabu, Nobuchika Kusano, Moriaki Wakuta, Nobuya Ogawa, Keizo Yamaguchi, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

We carried out a well-controlled study to evaluate the efficacy, safety, and usefulness of cefclidin (CFCL) in respiratory tract infections, using ceftazidime (CAZ) as the reference drug. Either CFCL or CAZ was given intravenously in a dose of 2 g daily (1 g b.i.d.) for 14 days as a rule. The following results were obtained: 1) The overall clinical efficacy rate assessed by attending physicians was 89.9% (62/69) for CFCL and 85.7% (72/84) for CAZ, and there was no statistically significant difference between the two agents. For moderate infections the efficacy rate and “excellent” response rate was significantly higher for CFCL than for CAZ (U-test, p<;0.05). In the judgment by the Efficacy Assessment Committee (Study Committee), the rates were 83.3% (60/70) for CFCL and 80.0% (68/85) for CAZ, with no statistically significant difference between the two agents. 2) With regard to bacteriological response, the eradication rate in monomicrobial infections was 91.2% (31/34) for CFCL and 69.2% (27/39) for CAZ (χ2-test, p<;0.05). The overall eradication rate was higher for CFCL than for CAZ, 90.5% (38/42) vs 72.5% (37/51). In particular, the eradication rate for Pseudomonas aeruginosa was 73.3% (11/15) for CFCL and 53.8% (14/26) for CAZ. 3) Adverse drug reactions were observed in 4.5% (4/89) in the CFCL group and 3.1% (3/96) in the CAZ group. The incidence of abnormal laboratory findings was judged by attending physicians to be 21.2% (18/85) in the CFCL group and 20.9% (19/91) in the CAZ group. The Study Committee rates were 23.5% (20/85) for CFCL and 26.4% (24/91) for CAZ. No severe symptoms or abnormal findings were observed, and there was no significant difference between the two drugs. 4) The usefulness rates judged by attending physicians were 88.4% (61/69) for CFCL and 82.1% (69/84) for CAZ (U-test, p<;0.05). The usefulness rates according to the Study Committee were 80.6% (58/72) for CFCL and 77.9% (67/86) for CAZ, with no significant difference. Based on the above results, it was concluded that CFCL is useful from the viewpoint of efficacy and safety in the treatment of respiratory tract infections. Since CFCL exhibits a potent in vitro activity and a high eradication rate against P. aeruginosa, it appears that this drug is likely to be useful in the treatment of refractory Pseudomonas respiratory infections.

Original languageEnglish
Pages (from-to)104-127
Number of pages24
JournalCHEMOTHERAPY
Volume41
Issue number1
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'A comparative study of cefclidin and ceftazidime in chronic respiratory tract infections'. Together they form a unique fingerprint.

Cite this